

# World Journal of *Anesthesiology*

*World J Anesthesiol* 2018 July 27; 7(2): 10-19





**REVIEW**

- 10 Targeting tumor necrosis factor in the brain relieves neuropathic pain

*Ignatowski TA, Spengler RN*

**ABOUT COVER**

Editorial Board Member of *World Journal of Anesthesiology*, Kar-Lok Wong, MD, PhD, Professor, Department of Anesthesia, China Medical University and Hospital, Taichung, Taiwan

**AIM AND SCOPE**

*World Journal of Anesthesiology* (*World J Anesthesiol*, *WJA*, online ISSN 2218-6182, DOI: 10.5313) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJA* covers topics concerning general anesthesia, local anesthesia, obstetric anesthesia, pediatric anesthesia, neurosurgical anesthesia, cardiovascular anesthesia, organ transplantation anesthesia, anesthesia complications, anesthesia monitoring, new techniques, quality control, airway management, volume therapy, pain diagnosis and treatment, and intensive care, as well as, evidence-based medicine, epidemiology and nursing. The current columns of *WJA* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography.

We encourage authors to submit their manuscripts to *WJA*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING**

*World Journal of Anesthesiology* is now indexed in China National Knowledge Infrastructure (CNKI).

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Yan Huang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Li-Jun Cui*  
**Proofing Editorial Office Director:** *Ya-Juan Ma*

**NAME OF JOURNAL**  
*World Journal of Anesthesiology*

**ISSN**  
 ISSN 2218-6182 (online)

**LAUNCH DATE**  
 December 27, 2011

**FREQUENCY**  
 Four-monthly

**EDITOR-IN-CHIEF**  
**Zhiyi Zuo, MD, PhD, Professor**, Department of Anesthesiology, University of Virginia, Charlottesville, PO Box 800710, VA 22908, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/2218-6182/editorialboard.htm>

**EDITORIAL OFFICE**  
 Ya-Juan Ma, Director

*World Journal of Anesthesiology*  
 Baishideng Publishing Group Inc  
 8226 Regency Drive, Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 8226 Regency Drive,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-223-8242  
 Fax: +1-925-223-8243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 July 27, 2018

**COPYRIGHT**  
 © 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
<http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>

## Targeting tumor necrosis factor in the brain relieves neuropathic pain

Tracey A Ignatowski, Robert N Spengler

Tracey A Ignatowski, Department of Pathology and Anatomical Sciences and Program for Neuroscience, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14203, United States

Tracey A Ignatowski, Robert N Spengler, NanoAxis, LLC, Clarence, NY 14031, United States

ORCID number: Tracey A Ignatowski (0000-0002-8033-4566); Robert N Spengler (0000-0001-7107-4013).

**Author contributions:** Ignatowski TA initiated the literature review; Ignatowski TA and Spengler RN equally contributed to the writing and revision of the manuscript.

**Conflict-of-interest statement:** Tracey A Ignatowski and Robert N Spengler have served as unpaid expert witnesses for the Institute of Neurological Recovery (INR), a medical practice that utilizes perispinal etanercept and trains physicians in its use as a therapeutic modality. Tracey Ignatowski and Robert Spengler's professional activities include their work as Co-Directors of Neuroscience at NanoAxis, LLC, a company formed to foster the commercial development of products and applications in the field of nanomedicine that include novel methods of inhibiting TNF. This article represents the authors' own work in which NanoAxis, LLC was not involved.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Tracey A Ignatowski, PhD, Assistant Professor, Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, 955 Main Street, Buffalo, NY 14203, United States. [ta1@buffalo.edu](mailto:ta1@buffalo.edu)

Telephone: +1-716-8293102

Fax: +1-716-8292725

Received: March 27, 2018

Peer-review started: April 12, 2018

First decision: May 3, 2018

Revised: May 28, 2018

Accepted: June 2, 2018

Article in press: June 2, 2018

Published online: July 27, 2018

### Abstract

Neuropathic pain is a chronic syndrome caused by direct damage to or disease of the somatosensory nervous system. The lack of safe, adequate and sustained pain relief offered by present analgesic treatments is most alarming. While many treatment options are available to manage chronic pain, such as antidepressants, non-steroidal anti-inflammatory agents, opioids, and anti-convulsants, chronic neuropathic pain remains largely unmanaged. Compounding the dilemma of ineffective chronic pain treatments is the need to provide relief from suffering and yet not contribute to the scourge of drug abuse. A recent epidemic of addiction and accidental drug prescription overdoses parallel the increased use of opioid treatment, even though opioids are rarely an effective treatment of relieving chronic pain. To make matters worse, opioids may contribute to exacerbating pain, and side-effects such as cognitive impairment, nausea, constipation, development of tolerance, as well as their potential for addiction and overdose deaths exist. Clearly, there is an urgent need for alternative, non-opiate treatment of chronic pain. Innovative discoveries of pertinent brain mechanisms and functions are key to developing effective, safe treatments. Pioneering work has revealed the essential effects of the pleiotropic mediator tumor necrosis factor (TNF) on brain functioning. These studies establish that TNF inhibits norepinephrine

release from hippocampal neurons, and show that excess TNF production within the hippocampus occurs during neuropathic pain, which mobilizes additional mechanisms that further inhibit norepinephrine release. Significantly, it has been verified that elevated levels of TNF in the brain are actually required for neuropathic pain development. Since TNF decreases norepinephrine release in the brain, enhanced TNF levels would prevent engagement of the norepinephrine descending inhibitory neuronal pain pathways. Increased levels of TNF in the brain are therefore critical to the development of neuropathic pain. Therefore, strategies that decrease this enhanced TNF expression in the brain will have superior analgesic efficacy. We propose this novel approach of targeting the pathologically high levels of brain TNF as an effective strategy in the treatment of the devastating syndrome of chronic pain.

**Key words:** Neuropathic pain; Tumor necrosis factor; Brain; Norepinephrine; Analgesia

© **The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Chronic pain is a widespread health problem. Current treatments, including opioids or non-steroidal anti-inflammatory drugs are inadequate as they lack sufficient efficacy, produce numerous side effects and hold the potential for addiction. Preclinical studies show that elevated brain tumor necrosis factor (TNF) levels during chronic pain are a novel target for producing analgesia. TNF can be practically targeted by non-invasive delivery of anti-TNF biologics directly to the ventricles of the brain *via* a peripheral perispinal injection. Herein we discuss decreasing TNF activity in the brain as a treatment to provide a superior analgesic strategy. Animal study results indicate potential benefit for patients with treatment-resistant pain.

Ignatowski TA, Spengler RN. Targeting tumor necrosis factor in the brain relieves neuropathic pain. *World J Anesthesiol* 2018; 7(2): 10-19 Available from: URL: <http://www.wjgnet.com/2218-6182/full/v7/i2/10.htm> DOI: <http://dx.doi.org/10.5313/wja.v7.i2.10>

## INTRODUCTION

Neuropathic pain is a prevalent, chronic disease syndrome caused by injury to peripheral nerves, the spinal cord, or the brain. It affects over 20 million people and costs in excess of \$500 billion per year in lost productivity and expenses<sup>[1,2]</sup>. In addition, it inflicts a tremendous amount of suffering and devastating effects on both the patient and loved ones. For those reasons, innovative breakthroughs are very much needed to replace current treatments, which have proven ineffective in treating this devastating health dilemma. The present therapeutic management of

neuropathic pain with medications including opioids, non-steroidal anti-inflammatory drugs, antidepressants, and anticonvulsants is often ineffective in providing adequate as well as sustained pain relief. The next generation of analgesics (anti-pain medications) will be developed by exploiting the current knowledge of chronic inflammation, a pathophysiological response now known to direct fundamental mechanisms involved in the perception of pain. Novel treatment design will selectively target brain-mediators that are directly enhanced by nerve injury, are involved with the chronic inflammation, and very importantly are also localized to the brain regions associated with the perception of pain. Crucial to the understanding of the etiology of neuropathic pain is that many inflammatory mediators are also neuromodulators. A peripheral insult with its accompanying local inflammation produces an associated expression of inflammatory cytokines (inflammatory mediator proteins) in the brain, which subsequently directs profound neuromodulatory mechanisms that ultimately modify neurotransmitter release. It is becoming apparent that the effective treatment of neuropathic pain requires targeting the production of those brain (central nervous system, CNS) pleiotropic inflammatory cytokines. A particularly important cytokine that is also a neuromodulator target within the brain is tumor necrosis factor (TNF), because of its proximal function. In fact, TNF is often referred to as a pro-inflammatory cytokine; this implies that this protein mediator is a marker for inflammation since it sets into motion a myriad of events crucial in the inflammatory response. However, this pleiotropic mediator is involved in a myriad of physiologic processes including modifying release of neurotransmitters<sup>[3-7]</sup> and homeostatic regulation of the blood-brain barrier<sup>[8]</sup>. Yet, when it is increased in the level of expression or enhanced for an extended duration of time, TNF can instigate pathophysiologic changes; this is the case during neuropathic pain conditions. As a neuromodulator, TNF modifies both the perception of pain as well as brain-body communication directing the peripheral inflammatory loci<sup>[9,10]</sup>. Preclinical investigation and clinical case studies involving blocking the responses of this brain-derived protein and its mechanisms of action during neuropathic pain show great efficacy, with minimal side-effects, and has decreased or no apparent potential for drug abuse<sup>[9,11,12]</sup>. Accordingly, cutting-edge investigations into the role of brain-derived TNF in chronic pain etiology indicate that pioneering therapeutic approaches are on the horizon, and urgency in their development is paramount based on the rising epidemic of prescription opioid drug abuse and resurgence in heroin use by desperate and hopeless individuals. Current preclinical studies reveal an advanced breakthrough in treatment efficacy for the debilitating and life-threatening illness of neuropathic pain, by blocking the higher levels of TNF that are specifically within the brain during the onset, development and maintenance of this devastating disease<sup>[9,10,12-14]</sup>.

## THERAPEUTIC TARGET LOCATED WITHIN THE BRAIN DURING THE ONSET AND DEVELOPMENT OF NEUROPATHIC PAIN

Improved therapeutic approaches require a greater understanding of the pathogenic mechanisms that create, develop, and propagate neuropathic pain. The perception and experience of pain manifests in select brain loci *via* molecular signaling; therefore, brain-derived protein mediators, such as pro-inflammatory cytokines (neuromodulators), along with neurotransmitters that are linked to neuropathic pain pose novel targets for analgesia. The functional interactive and mechanistic relationships that exist between the classical neurotransmitters and these protein neuromodulators (mediators) are being realized. In particular, how these relationships direct both normal as well as pathological brain functions is offering new insights into etiologies of disease syndromes. For instance, TNF produced either in the CNS or systemically has been implicated or has been shown to play a key role in the onset, development and maintenance of neuropathic pain. This is because increases in inflammatory cytokines occur rapidly after injury, and TNF as a proximal mediator initiates the cytokine cascade<sup>[15,16]</sup>. In fact, TNF drives the release of inflammatory cytokines, including IL-1 $\beta$ , IL-6, and itself, all of which are involved in chronic pain, and it robustly alters neurotransmission (glutamate and norepinephrine) in the CNS<sup>[5,13]</sup>. TNF levels rise locally and centrally after peripheral nerve injury<sup>[13,14,17-21]</sup>. Substantial data reveal pro-nociceptive roles for TNF in chronic pain<sup>[22-24]</sup>, and increases in levels of TNF in the brain impact peripheral hypersensitivity<sup>[9,14,25,26]</sup>. Thus, whether the increase is central, peripheral or both, TNF facilitates pain<sup>[27,28]</sup>, and lowering of TNF is antinociceptive<sup>[12,14,29-34]</sup>. Spread of inflammation occurs along the neuroaxis (CNS and peripheral nervous system, PNS) during neuropathic pain, providing an explanation for its chronicity<sup>[35]</sup>. The chronic pain state may exist from signal-induced TNF, IL-1 $\beta$ , and IL-6 production distant from the injury or from transport of cytokines to the CNS from the periphery. These cytokines induce neuroplasticity leading to chronicity of pain. In fact, chronic pain is centralized by maladaptive CNS functions that greatly alter brain systems, whether started in the PNS or CNS<sup>[36]</sup>. The enhanced production of TNF in the region of the brain known as the hippocampus, which is involved in memory formation and learning, is observed during sciatic nerve constriction-induced pain behavior<sup>[9,12-14]</sup>. In fact, it is now evident that enhanced TNF expression in specific brain regions is sufficient as well as necessary for the expression of pain behaviors. Ectopically enhanced expression of TNF (nanoparticle-bound TNF-expression plasmids) that is solely administered into and thus only found within the hippocampus generates a pain response that mirrors the hyperalgesia and allodynia that is normally associated with neuropathic pain<sup>[26]</sup>. This experimental study thus mimics the overexpression

of brain TNF that occurs during the evolution of chronic pain, and results in peripheral hypersensitivity in the absence of nerve injury<sup>[9,13,14,26]</sup>. Based on these findings, it may be concluded that a treatment that exclusively or directly targets this increased production of TNF in the brain during neuropathic pain onset and development should provide greater therapeutic efficacy against this chronic disease syndrome. In addition, targeting CNS TNF activity would avoid the deleterious side effects associated with peripheral targets. In support of this therapeutic paradigm, alleviation of hyperalgesia occurs following intra-hippocampal injection of TNF-siRNA-complexed (bound) nanoparticles that prevent translation of TNF gene expression that is solely found within this brain region<sup>[12]</sup>. Thus, the therapeutic prevention of TNF expression that is specifically located in the hippocampus prevents the onset and development of peripheral hypersensitivity associated with peripheral nerve injury. These studies confirm that the overexpressed TNF that occurs in the hippocampus during the onset, development and maintenance of neuropathic pain is pathogenic and is a promising putative target for anti-nociceptive therapy<sup>[12,14,26]</sup>.

## NEUROTOXICITY MEDIATED BY TNF CONTRIBUTES TO THE CHRONIC PAIN PHENOTYPE

Patients with diverse chronic pain states have reduced brain region volumes, which highlights the linkage of the brain to chronic pain. The volume of the hippocampus is reduced with back pain, osteoarthritis, or complex regional pain syndrome. Similarly, mice with neuropathic pain have decreased hippocampal neurogenesis<sup>[37]</sup>. Prolonged, elevated TNF may reduce gray matter volume, since increased TNF appears to decrease neurogenesis in a neuropathic pain model<sup>[38]</sup> and enhances production of glutamate, which is neurotoxic when in excess<sup>[6,39]</sup>. Of note, even chronic low back pain patients treated with morphine show reduced gray matter volume<sup>[40]</sup>. Thus, ample evidence indicates TNF as a novel, non-opioid associated key mediator of chronic pain, and its dysregulated production in the CNS as vital to pain chronicity.

TNF is produced not only by immune/inflammatory cells, but also by brain neurons and glial cells<sup>[41]</sup>. Since microglia and neurons express both TNF receptor-1 (p55) and TNF receptor-2 (p75) (TNFR1 and TNFR2), and neuropathic pain development and maintenance is linked to signaling through TNFR1<sup>[38,42]</sup>, it is likely that microglial activation by TNF through TNFR1 mediates persistent TNF production that contributes to the ongoing neuroinflammation and neuropathological consequences including synaptic transmission deficits and decreased neurogenesis<sup>[13,43-46]</sup>. Since the initial characterization of the roles of TNF in both normal physiology as well as in pathological settings as a pro-inflammatory mediator, TNF was labeled as functioning as a double-edged sword.

Quite interesting, this also holds true with its role now as a neuromodulator. Physiologic levels of brain TNF control proliferation and are neuroprotective; conversely, at high pathologic levels, TNF creates neuron dysfunction and disorder<sup>[41]</sup>. Thus, much attention is directed toward TNF as it drives the production/release of cytokines, directly causes nociception, and regulates neurotransmission.

---

## TNF INHIBITS NOREPINEPHRINE RELEASE FROM BRAIN NORADRENERGIC NEURONS

---

Neuromodulation is the process whereby autocrine, paracrine or hormonal mediators will control the ability of a neuron to release its neurotransmitter; thus, the physiological levels of classic neurotransmitters are regulated by such neuromodulators and accordingly modify the function of neurons. This is, in fact, a classic neuro-immune response, showing how immune effector cells orchestrate the nervous system. Neuromodulators, including cytokines, function as a paracrine by diffusing through large regional areas of the brain (CNS), affecting multiple neurons and glial cells and consequently are a communication signal between the nervous and immune system. This neuro-immune communication has a major impact on brain function. Unlike the specific targeting of an individual neuron by its own neurotransmitter, which is rapidly degraded or reabsorbed, a neuromodulator controls the neuronal circuitry of an entire brain region. The neuro-immune mediator, TNF, and its communication network have a major impact on brain function, and the elevated levels of brain-TNF during neuropathologies provide a therapeutic target. Targeting these elevated levels of TNF within the brain, and thus its impact on numerous neurotransmitter systems, will revolutionize medicine by treating numerous disorders as an aberrant inflammatory response of the brain.

One of the neuromodulator functions of TNF is to inhibit the release of the neuron-derived monoamine neurotransmitter, norepinephrine, as shown in the isolated median eminence<sup>[47]</sup>. TNF also inhibits the release of norepinephrine from field-stimulated tissue slices of the hippocampus, a region rich in noradrenergic nerve terminals<sup>[3,4]</sup>. Neuropathic pain, while directed by enhanced TNF production in the hippocampus, is also associated with reduced norepinephrine release within the brain<sup>[9,13,48]</sup>. Thus, this finding offers credibility to propose that a mechanism by which TNF directs neuropathic pain is through its enhanced and profound inhibitory effect on norepinephrine release. Overproduction of TNF in the hippocampus during neuropathic pain modifies signaling pathways to overwhelmingly inhibit norepinephrine release. Since supra-spinal descending noradrenergic inhibition of pain (endogenous analgesic pathway) occurs when norepinephrine is released in the brain<sup>[49,50]</sup>, the overproduction of TNF during neuropathic pain, with its enhanced inhibition of norepinephrine release, would

elevate pain to a chronic state by reducing central inhibition, thereby establishing a central component<sup>[9,13,48]</sup>. This mechanism explains how engagement of the descending inhibitory neuronal pain pathways is prevented as shown within the hippocampus. In fact, due to its direct sensory input from the spinal cord, indirect sensory input from other brain regions, and complex network connections to thalamic and parabrachial regions, the hippocampus is well-situated to participate in both pain processing and modulation<sup>[51]</sup>. Hence, the development of neuropathic pain is dependent upon the neuromodulatory role of the pathologically elevated levels of TNF in the hippocampus. In fact, the therapeutic mechanism by which antidepressant drugs provide analgesia during neuropathic pain is most possibly due to their ability to inhibit TNF production in the brain, and in particular in the hippocampus<sup>[10]</sup>, as they do for the alleviation of depressive behaviors<sup>[52,53]</sup>. It follows then, strategies that decrease TNF expression in the hippocampus would be expected to produce greater therapeutic efficacy. It is becoming increasingly evident that there are clear functional links between brain production of TNF and the development of neuropathic pain<sup>[51]</sup>. More importantly, it is imperative to elucidate the mechanisms that are involved in the pathogenesis of neuropathic pain and which are secondary to the enhanced expression of TNF in the hippocampus. The development of novel therapeutic approaches that specifically target the increased levels of TNF in the brain of patients promises superior treatments for hard-to-treat chronic pain, such as neuropathic pain.

---

## TRICYCLIC ANTIDEPRESSANT DRUG ANALGESIC MECHANISM OF ACTION

---

Of the millions of patients who suffer from devastating chronic pain, many are additionally diagnosed with neuropathic pain that is mediated by peripheral nerve injury<sup>[54,55]</sup>. Unlike acute pain, effective safe treatment for neuropathic pain has been elusive. Morphine derivatives are often prescribed for treatment of chronic pain conditions, including neuropathic pain. However, it has been shown that morphine repeatedly given to rats increases TNF expression in microglia, resident macrophage cells of the brain<sup>[56,57]</sup>. This finding explains morphine-induced hyperalgesia and/or tolerance that develops during chronic pain treatment, since TNF contributes to the chronic pain state<sup>[58]</sup>. Of interest, etanercept, a TNF blocker (a human TNFR2 fusion protein that blocks activity of TNF), when given intrathecally to morphine-tolerant rats decreased spinal TNF, IL-1 $\beta$ , IL-6 production and restored the antinociceptive effect of morphine<sup>[56]</sup>. This effect supports the contraindication of morphine as a chronic pain therapeutic.

We reported clinical benefit from perioperative clonidine use; clonidine lowered TNF levels in the cerebrospinal fluid, lowered patient VAS pain scores, and reduced postoperative morphine need<sup>[59,60]</sup>. Clonidine

manages pain mediated from elevated brain TNF, which causes neuroplasticity, that allows for transient pain relief<sup>[9,13,61]</sup>. Yet, as with most drugs, clonidine has adverse side-effects limiting its use. Despite its benefits in pain management, this drug is mostly used as an adjunct to other analgesics (opioids, nonsteroidal anti-inflammatory drugs).

Tricyclic antidepressant drugs as well as anti-convulsant drugs are first-line remedies for neuropathic pain<sup>[62-66]</sup>, yet neither class of drugs effectively treats all patients. While tricyclic antidepressant drugs are employed as a treatment practice, they are only moderately effective largely due to their various additional side-effects, and these multiple, unwanted side-effects limit their use<sup>[67,68]</sup>. The tricyclic antidepressant drug analgesic mechanism of action is proposed to involve various neurotransmitter effectors (norepinephrine, serotonin, dopamine, and acetylcholine), which are dysregulated (both at their release as well as at receptor response) during neuropathic pain. Studies suggest that the tricyclic antidepressant drug analgesic mechanism involves their capacity to increase monoamines (NE, serotonin) in the synaptic cleft (at the varicosities) of neurons within the brain. Therefore, as proposed above, enhanced synaptic levels of monoamines activate the descending inhibitory pain pathway, which is compromised during neuropathic pain<sup>[64]</sup>. In fact, tricyclic antidepressants and norepinephrine reuptake inhibitors (duloxetine, milnacipran) are better for neuropathic pain than SSRIs (Prozac, fluoxetine)<sup>[69,70]</sup>. This may occur because, although each monoamine can activate both descending pain inhibitory and facilitatory pathways<sup>[71,72]</sup>, brain norepinephrine preferentially activates descending pain inhibitory pathways<sup>[73]</sup>, whereas serotonin promotes descending pain facilitation<sup>[74]</sup>. At the same time, tricyclic antidepressant drug-mediated increase of peripheral-monoamines would enhance afferent pain signal transmission; therefore, tricyclic antidepressant drug analgesic action must occur specifically within the brain to be the most efficacious. In support, during chronic constriction injury (CCI)-induced neuropathic pain, increases in TNF levels occur in the periphery (injured sciatic nerve) as well as in the brain; yet, treatment with amitriptyline (tricyclic antidepressant drug, intraperitoneal injection) only decreased TNF production in the brain (hippocampus) and not in the spinal cord concomitant with alleviation of pain<sup>[10]</sup>. Thus, the reduction of peripheral TNF production can be an unwarranted side-effect, where inflammatory responses may be necessary for healing or to combat associated infections. Specifically, we found that chronic treatment with amitriptyline, when initiated early after peripheral injury, reduced brain TNF and alleviated CCI-induced peripheral hypersensitivity<sup>[10]</sup>. In contrast, we showed that acute amitriptyline treatment, at peak hyperalgesia, only briefly blocked CCI-induced hyperalgesia, but enhanced total brain TNF level<sup>[48]</sup>. Thus, increased brain norepinephrine release is required for antinociception. Amitriptyline increases brain norepinephrine release (through reuptake

inhibition and, as an additional effect, adjusting TNF production), which may be antinociceptive by increasing the activity of the descending inhibitory bulbospinal pathway (inactive during neuropathic pain)<sup>[75]</sup>. This acute, transient antinociceptive effect of amitriptyline is most likely explained by norepinephrine activation of presynaptic- $\alpha_2$ -adrenergic autoreceptor-coupled-Ga proteins that inhibit norepinephrine release. Of particular interest, their sensitivity to inhibit norepinephrine release is enhanced by TNF, thereby maintaining a chronic pain state due to preventing engagement of the descending inhibitory pain pathway<sup>[10]</sup>. While the  $\alpha_2$ -adrenergic agonist clonidine normally inhibits TNF production<sup>[61]</sup>, the transient analgesic effect by clonidine in the CCI model of neuropathic pain occurs at the time when we have established that the presynaptic- $\alpha_2$ -adrenergic receptor response to TNF actually switches from inhibiting to facilitating norepinephrine release<sup>[61]</sup>. We propose that while this plays a role in the natural dissipation of CCI-induced thermal hyperalgesia, it can be provoked by blocking TNF production and can be involved in resolving neuropathic pain in humans<sup>[48,61]</sup>.

The reduction in levels of TNF in the brain elicited by tricyclic antidepressant drugs appears to be the likely mechanism of action directing their off-label analgesic drug use. Since the perception of pain is a product of the brain, and brain synthesized TNF is a key factor in neuropathic pain development, the elevated amounts of TNF in the brain of neuropathic pain patients could profoundly influence various neurotransmitter effectors. It follows therefore, that brain-TNF production when selectively targeted would create a potent and efficacious therapy. As previously stated, while TNF is increased in the brain during animal neuropathic pain models<sup>[9,10,13,14]</sup>, TNF regulates norepinephrine release from noradrenergic nerve terminals, and norepinephrine release in the brain is decreased at the same time<sup>[13,14,48]</sup>, which supports a role for TNF in the neuroplasticity associated with the development and maintenance of neuropathic pain. Not only does TNF directly inhibit norepinephrine release, but TNF also modifies the response of the presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptor, a principal inhibitor of norepinephrine release<sup>[3,4]</sup>. The presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptor is activated by the release of norepinephrine in the synaptic cleft, as an inhibitory feedback mechanism having a primary effect on norepinephrine release. When activated, the presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptor decreases further release of norepinephrine upon depolarization. Of particular interest, not only do tricyclic antidepressant drugs decrease TNF production, but they are also known to down regulate and desensitize the presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptor<sup>[76,77]</sup>. This simultaneous double-hit response by tricyclic antidepressant drugs on TNF production and on the presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptor would have a profound response on depolarized release of norepinephrine culminating with analgesic functioning. It follows that the analgesic mechanism of tricyclic antidepressant drugs is likely the

result of their effect on TNF levels. Thus, the increased expression and levels of brain-TNF that are mediated by peripheral nerve injury is a viable therapeutic target<sup>[3,10]</sup>.

Founded on the fact that TNF regulates (inhibits) norepinephrine release in the brain both directly as well as indirectly by its effect on presynaptic  $\alpha_2$ -adrenergic autoinhibitory receptors, a pathologic increased level of TNF in the brain, and in particular, in the hippocampus, would be a key nociceptive target affecting norepinephrine bioavailability in the brain. Therefore, it follows that utilizing the inhibition of TNF activity as an antidepressant mechanism supports the monoamine theory of depression as well as the role of norepinephrine in the etiology of chronic pain. This current and comprehensive knowledge of inflammatory mediators such as TNF in chronic pain etiology will allow for the ushering in of new therapeutics that apply these mechanisms to direct the efficacy of new tricyclic antidepressant drug formulations or any other new therapies. Medicine that specifically reduces TNF levels in the brain are effective in animal models of neuropathic pain<sup>[29,30,78]</sup>. Unfortunately, FDA-approved anti-TNF drugs are designed to target peripheral TNF and not brain TNF (*i.e.*, Infliximab) and, therefore, have very limited access to the brain; this could explain conflicting clinical reports<sup>[11,79-81]</sup>. For instance, not all patients with sciatica receive benefit with peripherally administered TNF blockers<sup>[80,81]</sup>. Meanwhile, tricyclic antidepressant drugs that can alleviate pain do in fact decrease the production of TNF in the brain<sup>[10]</sup>; however, due to their mode of delivery, they produce significant side-effects that confound their efficacy<sup>[67,68]</sup>. Therefore, targeting the pathophysiologic levels of TNF that are specifically found within the brain, and in particular within the hippocampus, may be required to efficaciously alleviate pain. This premise is often incorrectly challenged by researchers/clinicians who administer anti-inflammatory drugs peripherally instead of through means that adequately target CNS-TNF alone. This is because when administered peripherally, a drug must distribute throughout the entire body where it is accessible and undergo metabolism through the liver, leaving significantly less unmetabolized drug to reach vital brain targets. Since very little drug reaches the brain when it is delivered peripherally, the (drug) effect on this organ would be minimal<sup>[82]</sup>. Even drug delivery *via* intrathecal injection, which delivers more drug to the brain than intravenous injection, is quite limited. Non-invasive drug administration that targets brain effectors would be a pioneering discovery with wide ranging potential for numerous brain disorders.

Blockade of TNF activity specifically in the brain is difficult due to the large size and structure of anti-TNF biologics such that they do not easily cross the blood-brain barrier. Therefore, a new pioneering breakthrough is underway. Perispinal injection is a subcutaneous, peri-venous route for delivery to the brain that is less invasive than epidural or intrathecal

routes<sup>[83]</sup>. Drugs injected outside and posterior to the spine (ligamentum flavum and spinal canal) are absorbed by the external vertebral venous plexus, part of the cerebrospinal venous system, which is a direct pathway to the brain<sup>[84]</sup>. Perispinal etanercept injection immediately followed with head-down positioning (Trendelenburg positioning) delivers the TNF fusion protein into the choroid plexus and cerebral ventricles in minutes, as shown by PET scan<sup>[85]</sup>. In fact, discogenic back pain patients that received perispinal etanercept delivery reported substantial, sustained recovery that was verified by reduction in Oswestry scores<sup>[11]</sup>. Also, patients reduced significantly or completely discontinued analgesic medication after perispinal etanercept. This included 11 of 20 patients requiring chronic opioids<sup>[11]</sup>. More recently, we reported a case study whereby perispinal injection of etanercept was performed to treat neurological dysfunction, including pain, induced by a traumatic brain injury suffered several years prior<sup>[86]</sup>. The results from this case indicate that even years after an acute brain injury, the pathologic levels of TNF induced by the injury may provide a feasible therapeutic target. Taken together, these case reports provide compelling evidence that the specific targeting of brain-TNF is superior and thus an effective analgesic.

---

## ROLES FOR TNF IN NEUROPATHIC PAIN ETIOLOGY

---

There are multiple roles for TNF in the development and maintenance of neuropathic pain. While many animal model studies show that systemic levels of TNF increase during neuropathic pain and contribute to its pathology<sup>[19,87,88]</sup>, increased TNF levels specifically in select brain regions alone enhance or initiate peripheral hyperalgesia (increased noxious sensitivity), which is a typical neuropathic pain response<sup>[26]</sup>. The increased levels of TNF within the brain direct neuropathic pain onset<sup>[9,13,14,48]</sup>, as shown in the sciatic nerve CCI model<sup>[9,61,89]</sup>. Likewise, the neuropathic pain that develops during diabetes, diabetic neuropathy, is accompanied by high serum TNF levels<sup>[90-92]</sup>. High peripheral TNF levels in diabetes are associated with and possibly trigger peripheral nerve dysfunction and death<sup>[93,94]</sup>. Interestingly, TNF directs neuron responsiveness, similar to the immune effector cell, the macrophages, and thus TNF stimulates neurons to produce more TNF<sup>[4,61,95,96]</sup>. This creates a perpetuating feed-forward cycle, whereby inflammatory mediators released from damaged neurons stimulate cells and result in further production of TNF<sup>[97]</sup>. This perpetual cycle may ultimately result in neuronal death, causing atrophy, which is an effect of TNF that may contribute to the decrease in brain gray matter experienced by chronic pain patients<sup>[98]</sup>. This atrophy effect may be due to increased glutamate release by TNF, since excessive glutamate is neurotoxic<sup>[39]</sup>. However, this effect, one of the many pleiotropic responses to TNF, may reflect the originally defined function of TNF as a

'tumor necrosis factor' or agent of cachexia or wasting syndrome. Moreover, the blockade of TNF activity by peripherally administered infliximab in rodent diabetes models restores glucose homeostasis<sup>[99]</sup>, but only reduces diabetic neuropathy<sup>[30]</sup>. This inefficient effect by peripheral TNF blockade is in contrast to the complete alleviation of neuropathic pain observed in the CCI model, when TNF was specifically blocked in the brain<sup>[9,12]</sup>. Mice deficient in TNF production (TNF $\alpha$ <sup>-/-</sup> mice) do not develop diabetic neuropathic pain following injection of streptozotocin (STZ), an antibiotic toxic to pancreatic  $\beta$ -islet cells and used to induce diabetes<sup>[30]</sup>. Thus, it is apparent that TNF has a pivotal role in neuropathic pain, and therapies that decrease systemic, but more importantly, brain levels of TNF will provide greater efficacious neuropathic pain treatment, and most importantly, with fewer side effects.

## CONCLUSION

In order to design novel therapies to treat neuropathic pain, it is necessary to use our current and comprehensive knowledge of biochemical mechanisms occurring specifically within the brain that elicit the development as well as the maintenance of neuropathic pain. An increased hippocampal TNF level plays a key role in the propagation and perception of neuropathic pain<sup>[9,13,14,26,48,61,89]</sup>. Since brain synthesized TNF modifies adrenergic neuron activity, it follows that sympathetic output is altered, and consequently, has profound effects on descending inhibitory pain pathways that normally provide endogenous analgesia. The limited success in treating neuropathic pain with current agents stems from lack of specific and selective targeting of a fundamental mechanism associated with pain perception such as the pathologically overexpressed TNF in the brain and in particular in the hippocampus<sup>[10,12,21,37]</sup>. In conclusion, elevated brain TNF levels drive the pathogenesis of neuropathic pain, and therapies that specifically lower this pathologic level of brain TNF may provide more efficacious chronic pain treatment, with fewer side effects and negligible abuse potential.

## REFERENCES

- 1 **National Institute of Neurological Disorders and Stroke (NINDS).** Peripheral Neuropathy Fact Sheet, NIH Pub, 2014: 15-4853
- 2 **van Hecke O,** Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. *Pain* 2014; **155**: 654-662 [PMID: 24291734 DOI: 10.1016/j.pain.2013.11.013]
- 3 **Ignatowski TA,** Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN. Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. *J Neuroimmunol* 1997; **79**: 84-90 [PMID: 9357451]
- 4 **Ignatowski TA,** Spengler RN. Tumor necrosis factor-alpha: presynaptic sensitivity is modified after antidepressant drug administration. *Brain Res* 1994; **665**: 293-299 [PMID: 7895065 DOI: 10.1016/0006-8993(94)91350-1]
- 5 **Santello M,** Bezzi P, Volterra A. TNF $\alpha$  controls glutamatergic

- gliotransmission in the hippocampal dentate gyrus. *Neuron* 2011; **69**: 988-1001 [PMID: 21382557 DOI: 10.1016/j.neuron.2011.02.003]
- 6 **Pickering M,** Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. *Exp Physiol* 2005; **90**: 663-670 [PMID: 15944202 DOI: 10.1113/expphysiol.2005.030734]
- 7 **Tancredi V,** D'Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A, Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. *Neurosci Lett* 1992; **146**: 176-178 [DOI: 10.1016/0304-3940(92)90071-E]
- 8 **Pan W,** Stone KP, Hsueh H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. *Curr Pharm Des* 2011; **17**: 3729-3740 [PMID: 21834767 DOI: 10.2174/138161211798220918]
- 9 **Ignatowski TA,** Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. *Brain Res* 1999; **841**: 70-77 [PMID: 10546989]
- 10 **Sud R,** Spengler RN, Nader ND, Ignatowski TA. Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes/macrophages from pro- to anti-inflammatory. *Eur J Pharmacol* 2008; **588**: 217-231 [PMID: 18514187 DOI: 10.1016/j.ejphar.2008.04.043]
- 11 **Tobinick E,** Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. *Curr Med Res Opin* 2004; **20**: 1075-1085 [PMID: 15265252 DOI: 10.1185/030079903125004286]
- 12 **Gerard E,** Spengler RN, Bonoiu AC, Mahajan SD, Davidson BA, Ding H, Kumar R, Prasad PN, Knight PR, Ignatowski TA. Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor. *Pain* 2015; **156**: 1320-1333 [PMID: 25851457 DOI: 10.1097/j.pain.000000000000181]
- 13 **Covey WC,** Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. *Brain Res* 2000; **859**: 113-122 [PMID: 10720620]
- 14 **Covey WC,** Ignatowski TA, Renaud AE, Knight PR, Nader ND, Spengler RN. Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain. *Reg Anesth Pain Med* 2002; **27**: 357-366 [PMID: 12132059 DOI: 10.1053/rapm.2002.31930]
- 15 **Madrigal JLM,** Hurtado O, Moro MA, Lizasoain I, Lorenzo P, Castrillo A, Bosca L, Leza JC. The increase in TNF- $\alpha$  levels is implicated in NF- $\kappa$ B activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. *Neuropsychopharm* 2002; **26**: 155-163 [DOI: 10.1016/S0893-133X(01)00292-5]
- 16 **O'Connor KA,** Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, Maier SF. Peripheral and central proinflammatory cytokine response to a severe acute stressor. *Brain Res* 2003; **991**: 123-132 [PMID: 14575884 DOI: 10.1016/j.brainres.2003.08.006]
- 17 **George A,** Schmidt C, Weishaupt A, Toyka KV, Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. *Exp Neurol* 1999; **160**: 124-132 [PMID: 10630197 DOI: 10.1006/exnr.1999.7193]
- 18 **Myers RR,** Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. *Drug Discov Today* 2006; **11**: 8-20 [PMID: 16478686 DOI: 10.1016/S1359-6446(05)03637-8]
- 19 **Schäfers M,** Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. *J Neurosci* 2003; **23**: 2517-2521 [PMID: 12684435 DOI: 10.1523/JNEUROSCI.23-07-02517.2003]
- 20 **Shubayev VI,** Angert M, Dolkas J, Campana WM, Palenscar K, Myers RR. TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. *Mol Cell Neurosci* 2006; **31**: 407-415 [PMID: 16297636 DOI: 10.1016/j.mcn.2005.10.011]

- 21 **Ren WJ**, Liu Y, Zhou LJ, Li W, Zhong Y, Pang RP, Xin WJ, Wei XH, Wang J, Zhu HQ, Wu CY, Qin ZH, Liu G, Liu XG. Peripheral nerve injury leads to working memory deficits and dysfunction of the hippocampus by upregulation of TNF- $\alpha$  in rodents. *Neuropsychopharmacology* 2011; **36**: 979-992 [PMID: 21289602 DOI: 10.1038/npp.2010.236]
- 22 **Saab CY**, Waxman SG, Hains BC. Alarm or curse? The pain of neuroinflammation. *Brain Res Rev* 2008; **58**: 226-235 [PMID: 18486228 DOI: 10.1016/j.brainresrev.2008.04.002]
- 23 **Watkins LR**, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. *Brain Res* 1994; **654**: 15-26 [PMID: 7982088]
- 24 **Watkins LR**, Goehler LE, Relton J, Brewer MT, Maier SF. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. *Brain Res* 1995; **692**: 244-250 [PMID: 8548310]
- 25 **Oka T**, Wakugawa Y, Hosoi M, Oka K, Hori T. Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats. *Neuroimmunomodulation* 1996; **3**: 135-140 [PMID: 8945729 DOI: 10.1159/000097238]
- 26 **Martuscello RT**, Spengler RN, Bonoiu AC, Davidson BA, Helinski J, Ding H, Mahajan S, Kumar R, Bergey EJ, Knight PR, Prasad PN, Ignatowski TA. Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms. *Pain* 2012; **153**: 1871-1882 [PMID: 22770843 DOI: 10.1016/j.pain.2012.05.028]
- 27 **Liu YL**, Zhou LJ, Hu NW, Xu JT, Wu CY, Zhang T, Li YY, Liu XG. Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK. *Neuropharmacology* 2007; **52**: 708-715 [PMID: 17084420 DOI: 10.1016/j.neuropharm.2006.09.011]
- 28 **Liu B**, Li H, Brull SJ, Zhang JM. Increased sensitivity of sensory neurons to tumor necrosis factor alpha in rats with chronic compression of the lumbar ganglia. *J Neurophysiol* 2002; **88**: 1393-1399 [PMID: 12205160 DOI: 10.1152/jn.2002.88.3.1393]
- 29 **Dogrul A**, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. *Acta Diabetol* 2011; **48**: 135-142 [PMID: 21104419 DOI: 10.1007/s00592-010-0237-x]
- 30 **Yamakawa I**, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Sanada M, Kawai H, Chan L, Yasuda H, Maegawa H, Kimura H. Inactivation of TNF- $\alpha$  ameliorates diabetic neuropathy in mice. *Am J Physiol Endocrinol Metab* 2011; **301**: E844-E852 [PMID: 21810933 DOI: 10.1152/ajpendo.00029.2011]
- 31 **Hao S**, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. *Gene Ther* 2007; **14**: 1010-1016 [PMID: 17443214 DOI: 10.1038/sj.gt.3302950]
- 32 **Sommer C**, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. *Brain Res* 2001; **913**: 86-89 [PMID: 11532251]
- 33 **Hess A**, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, Sergeeva M, Saake M, Garcia M, Kollias G, Straub RH, Sporns O, Doerfler A, Brune K, Schett G. Blockade of TNF- $\alpha$  rapidly inhibits pain responses in the central nervous system. *Proc Natl Acad Sci USA* 2011; **108**: 3731-3736 [PMID: 21245297 DOI: 10.1073/pnas.1011774108]
- 34 **Chakravarthy K**, Faltus R, Robinson G, Sevilla R, Shin J, Zielstorff M, Byford A, Leccese E, Caniga MJ, Hseih S, Zhang S, Chiu CS, Zhang-Hoover J, Moy LY, McLeod RL, Stoffregen D, Zhang W, Murtaza A, Cicmil M. Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis. *BMC Musculoskelet Disord* 2014; **15**: 409 [PMID: 25477192 DOI: 10.1186/1471-2474-15-409]
- 35 **Cooper MS**, Clark VP. Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome. *J Neuroimmune Pharmacol* 2013; **8**: 452-469 [PMID: 22923151 DOI: 10.1007/s11481-012-9392-x]
- 36 **Borsook D**. Neurological diseases and pain. *Brain* 2012; **135**: 320-344 [PMID: 22067541 DOI: 10.1093/brain/awr271]
- 37 **Mutso AA**, Radzicki D, Baliki MN, Huang L, Banisadr G, Centeno MV, Radulovic J, Martina M, Miller RJ, Apkarian AV. Abnormalities in hippocampal functioning with persistent pain. *J Neurosci* 2012; **32**: 5747-5756 [PMID: 22539837 DOI: 10.1523/JNEUROSCI.0587-12.2012]
- 38 **Dellarole A**, Morton P, Brambilla R, Walters W, Summers S, Bernardes D, Grilli M, Bethea JR. Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling. *Brain Behav Immun* 2014; **41**: 65-81 [PMID: 24938671 DOI: 10.1016/j.bbi.2014.04.003]
- 39 **Clark IA**, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. *J Neuroinflammation* 2016; **13**: 236 [PMID: 27596607 DOI: 10.1186/s12974-016-0708-2]
- 40 **Lin JC**, Chu LF, Stringer EA, Baker KS, Sayyid ZN, Sun J, Campbell KA, Younger JW. One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results. *Pain Med* 2016; **17**: 1497-1504 [PMID: 26814280 DOI: 10.1093/pm/pnv047]
- 41 **Pan W**, Zadina JE, Harlan RE, Weber JT, Banks WA, Kasting AJ. Tumor necrosis factor-alpha: a neuroinflammation in the CNS. *Neurosci Biobehav Rev* 1997; **21**: 603-613 [PMID: 9353794]
- 42 **Ohtori S**, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. *Spine (Phila Pa 1976)* 2004; **29**: 1082-1088 [PMID: 15131433 DOI: 10.1097/00007632-200405150-00006]
- 43 **Sakuma Y**, Ohtori S, Miyagi M, Ishikawa T, Inoue G, Doya H, Koshi T, Ito T, Yamashita M, Yamauchi K, Suzuki M, Moriya H, Takahashi K. Up-regulation of p55 TNF alpha-receptor in dorsal root ganglia neurons following lumbar facet joint injury in rats. *Eur Spine J* 2007; **16**: 1273-1278 [PMID: 17468886 DOI: 10.1007/s00586-007-0365-3]
- 44 **Kuno R**, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. Autocrine activation of microglia by tumor necrosis factor-alpha. *J Neuroimmunol* 2005; **162**: 89-96 [PMID: 15833363 DOI: 10.1016/j.jneuroim.2005.01.015]
- 45 **Veroni C**, Gabriele L, Canini I, Castiello L, Coccia E, Remoli ME, Columba-Cabezas S, Aricò E, Aloisi F, Agresti C. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. *Mol Cell Neurosci* 2010; **45**: 234-244 [PMID: 20600925 DOI: 10.1016/j.mcn.2010.06.014]
- 46 **Zhang H**, Zhang H, Dougherty PM. Dynamic effects of TNF- $\alpha$  on synaptic transmission in mice over time following sciatic nerve chronic constriction injury. *J Neurophysiol* 2013; **110**: 1663-1671 [PMID: 23864372 DOI: 10.1152/jn.01088.2012]
- 47 **Elenkov IJ**, Kovács K, Duda E, Stark E, Vizi ES. Presynaptic inhibitory effect of TNF-alpha on the release of noradrenaline in isolated median eminence. *J Neuroimmunol* 1992; **41**: 117-120 [PMID: 1460089]
- 48 **Ignatowski TA**, Sud R, Reynolds JL, Knight PR, Spengler RN. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). *Neuropharmacology* 2005; **48**: 448-460 [PMID: 15721177 DOI: 10.1016/j.neuropharm.2004.11.001]
- 49 **Fields HL**, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. *Annu Rev Neurosci* 1991; **14**: 219-245 [PMID: 1674413 DOI: 10.1146/annurev.ne.14.030191.001251]
- 50 **Muto Y**, Sakai A, Sakamoto A, Suzuki H. Activation of NK<sub>1</sub> receptors in the locus coeruleus induces analgesia through noradrenergic-mediated descending inhibition in a rat model of neuropathic pain. *Br J Pharmacol* 2012; **166**: 1047-1057 [PMID: 22188400 DOI: 10.1111/j.1476-5381.2011.01820.x]
- 51 **Fasick V**, Spengler RN, Samankan S, Nader ND, Ignatowski TA. The hippocampus and TNF: Common links between chronic pain and depression. *Neurosci Biobehav Rev* 2015; **53**: 139-159 [PMID:

- 25857253 DOI: 10.1016/j.neubiorev.2015.03.014]
- 52 **Reynolds JL**, Ignatowski TA, Sud R, Spengler RN. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor- $\alpha$  production culminating in increases in noradrenergic neurotransmission. *Neuroscience* 2005; **133**: 519-531 [PMID: 15878644 DOI: 10.1016/j.neuroscience.2005.02.023]
  - 53 **Reynolds JL**, Ignatowski TA, Sud R, Spengler RN. Brain-derived tumor necrosis factor- $\alpha$  and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. *J Pharmacol Exp Ther* 2004; **310**: 1216-1225 [PMID: 15082752 DOI: 10.1124/jpet.104.067835]
  - 54 **Kibiuk LV**, Stuart D, Miller M. Brain facts: A primer on the brain and nervous system. *eNeuro* 2008; 49-50
  - 55 **Marx J**. Pain research. Prolonging the agony. *Science* 2004; **305**: 326-329 [PMID: 15256650 DOI: 10.1126/science.305.5682.326]
  - 56 **Shen CH**, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. *Anesth Analg* 2011; **112**: 454-459 [PMID: 21081778 DOI: 10.1213/ANE.0b013e3182025b15]
  - 57 **Shen CH**, Tsai RY, Wong CS. Role of neuroinflammation in morphine tolerance: effect of tumor necrosis factor- $\alpha$ . *Acta Anaesthesiol Taiwan* 2012; **50**: 178-182 [PMID: 23385041 DOI: 10.1016/j.aat.2012.12.004]
  - 58 **Angst MS**, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology* 2006; **104**: 570-587 [PMID: 16508405 DOI: 10.1097/00000542-200603000-00025]
  - 59 **Nader ND**, Ignatowski TA, Kurek CJ, Knight PR, Spengler RN. Clonidine suppresses plasma and cerebrospinal fluid concentrations of TNF- $\alpha$  during the perioperative period. *Anesth Analg* 2001; **93**: 363-369, 3rd contents page [PMID: 11473862 DOI: 10.1213/0000539-200108000-00026]
  - 60 **Nader ND**, Li CM, Dosluoglu HH, Ignatowski TA, Spengler RN. Adjuvant therapy with intrathecal clonidine improves postoperative pain in patients undergoing coronary artery bypass graft. *Clin J Pain* 2009; **25**: 101-106 [PMID: 19333153 DOI: 10.1097/AJP.0b013e3181817add]
  - 61 **Spengler RN**, Sud R, Knight PR, Ignatowski TA. Antinociception mediated by  $\alpha(2)$ -adrenergic activation involves increasing tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) expression and restoring TNF $\alpha$  and  $\alpha(2)$ -adrenergic inhibition of norepinephrine release. *Neuropharmacology* 2007; **52**: 576-589 [PMID: 17055005 DOI: 10.1016/j.neuropharm.2006.08.027]
  - 62 Duloxetine (Cymbalta) for diabetic neuropathic pain. *Med Lett Drugs Ther* 2005; **47**: 67-68 [PMID: 16103866]
  - 63 **Fishbain DA**, Cutler R, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. *Pain Med* 2000; **1**: 310-316 [PMID: 15101877 DOI: 10.1046/j.1526-4637.2000.00042.x]
  - 64 **Micó JA**, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. *Trends Pharmacol Sci* 2006; **27**: 348-354 [PMID: 16762426 DOI: 10.1016/j.tips.2006.05.004]
  - 65 **Saarto T**, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 2014; CD005454 [DOI: 10.1002/14651858.CD005454.pub2]
  - 66 **Iyer S**, Tanenberg RJ. Pharmacologic management of diabetic peripheral neuropathic pain. *Expert Opin Pharmacother* 2013; **14**: 1765-1775 [PMID: 23800105 DOI: 10.1517/14656566.2013.811490]
  - 67 **Dworkin RH**, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmdar KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc* 2010; **85**: S3-14 [PMID: 20194146 DOI: 10.4065/mcp.2009.0649]
  - 68 **Finnerup NB**, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015; **14**: 162-173 [PMID: 25575710 DOI: 10.1016/S1474-4422(14)70251-0]
  - 69 **Wright A**, Luedtke KE, Vandenberg C. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. *J Pain Res* 2010; **4**: 1-10 [PMID: 21386950 DOI: 10.2147/JPR.S12866]
  - 70 **Lunn MP**, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev* 2014; CD007115 [PMID: 24385423 DOI: 10.1002/14651858.CD007115.pub3]
  - 71 **Nuseir K**, Proudfit HK. Bidirectional modulation of nociception by GABA neurons in the dorsolateral pontine tegmentum that tonically inhibit spinally projecting noradrenergic A7 neurons. *Neuroscience* 2000; **96**: 773-783 [PMID: 10727795]
  - 72 **Buhler AV**, Proudfit HK, Gebhart GF. Neurotensin-produced antinociception in the rostral ventromedial medulla is partially mediated by spinal cord norepinephrine. *Pain* 2008; **135**: 280-290 [PMID: 17664042 DOI: 10.1016/j.pain.2007.06.010]
  - 73 **Yeomans DC**, Clark FM, Paice JA, Proudfit HK. Antinociception induced by electrical stimulation of spinally projecting noradrenergic neurons in the A7 catecholamine cell group of the rat. *Pain* 1992; **48**: 449-461 [PMID: 1594267]
  - 74 **Cai YQ**, Wang W, Hou YY, Pan ZZ. Optogenetic activation of brainstem serotonergic neurons induces persistent pain sensitization. *Mol Pain* 2014; **10**: 70 [PMID: 25410898 DOI: 10.1186/1744-8069-10-70]
  - 75 **Ardid D**, Jourdan D, Mestre C, Villanueva L, Le Bars D, Eschalier A. Involvement of bulbospinal pathways in the antinociceptive effect of clomipramine in the rat. *Brain Res* 1995; **695**: 253-256 [PMID: 8556340]
  - 76 **Smith CB**, Garcia-Sevilla JA.  $\alpha(2)$ -adrenoreceptors in endogenous depression. *Adv Biosci* 1982; **40**: 99-106
  - 77 **Yoshioka M**, Matsumoto M, Numazawa R, Togashi H, Smith CB, Saito H. Changes in the regulation of 5-hydroxytryptamine release by  $\alpha(2)$ -adrenoreceptors in the rat hippocampus after long-term desipramine treatment. *Eur J Pharmacol* 1995; **294**: 565-570 [PMID: 8750719]
  - 78 **Chauhan N**, Taliyan R, Sharma PL. Effect of dipyron and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain. *Naunyn Schmiedebergs Arch Pharmacol* 2012; **385**: 527-538 [PMID: 22249337 DOI: 10.1007/s00210-011-0724-9]
  - 79 **Cohen SP**, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC 3rd, Griffith S, Larkin TM, Dahl E, Morlando BJ. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. *Anesthesiology* 2007; **107**: 99-105 [PMID: 17585221 DOI: 10.1097/01.anes.0000267518.20363.0d]
  - 80 **Korhonen T**, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C, Hammond A, Kirkham B, Järvinen S, Niinimäki J, Veeger N, Haapea M, Torkki M, Tervonen O, Seitsalo S, Hurri H. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. *Spine (Phila Pa 1976)* 2006; **31**: 2759-2766 [PMID: 17108825 DOI: 10.1097/01.brs.0000245873.23876.1e]
  - 81 **Korhonen T**, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Järvinen S, Niinimäki J, Veeger N, Seitsalo S, Hurri H. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. *Spine (Phila Pa 1976)* 2005; **30**: 2724-2728 [PMID: 16371894 DOI: 10.1097/01.brs.0000190815.13764.64]
  - 82 **Banks WA**, Plotkin SR, Kastin AJ. Permeability of the blood-brain barrier to soluble cytokine receptors. *Neuroimmunomodulation* 1995; **2**: 161-165 [PMID: 8646566 DOI: 10.1159/000096887]
  - 83 **Tobinick EL**. Perispinal Delivery of CNS Drugs. *CNS Drugs* 2016; **30**: 469-480 [PMID: 27120182 DOI: 10.1007/s40263-016-0339-2]
  - 84 **Nathoo N**, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. *Neurosurgery* 2011; **69**: 1007-14; discussion 1014 [PMID: 21654535 DOI: 10.1227/NEU.0b013e3182274865]
  - 85 **Tobinick EL**, Chen K, Chen X. Rapid intracerebroventricular

- delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. *BMC Res Notes* 2009; **2**: 28 [PMID: 19284700 DOI: 10.1186/1756-0500-2-28]
- 86 **Tobinick E**, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. *Clin Drug Investig* 2014; **34**: 361-366 [PMID: 24647830 DOI: 10.1007/s40261-014-0186-1]
- 87 **Sommer C**, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. *Pain* 1998; **74**: 83-91 [PMID: 9514564]
- 88 **Wagner R**, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. *Neuroreport* 1996; **7**: 2897-2901 [PMID: 9116205 DOI: 10.1097/00001756-199611250-00018]
- 89 **Sud R**, Ignatowski TA, Lo CP, Spengler RN. Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain. *Brain Behav Immun* 2007; **21**: 112-124 [PMID: 16859892 DOI: 10.1016/j.bbi.2006.06.001]
- 90 **Cameron NE**, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. *Curr Drug Targets* 2008; **9**: 60-67 [PMID: 18220713 DOI: 10.2174/138945008783431718]
- 91 **Doupis J**, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. *J Clin Endocrinol Metab* 2009; **94**: 2157-2163 [PMID: 19276232 DOI: 10.1210/jc.2008-2385]
- 92 **González-Clemente JM**, Mauricio D, Richart C, Broch M, Caixàs A, Megia A, Giménez-Palop O, Simón I, Martínez-Riquelme A, Giménez-Pérez G, Vendrell J. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. *Clin Endocrinol (Oxf)* 2005; **63**: 525-529 [PMID: 16268804 DOI: 10.1111/j.1365-2265.2005.02376.x]
- 93 **Satoh J**, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. *Exp Diabetes Res* 2003; **4**: 65-71 [PMID: 14630568 DOI: 10.1155/EDR.2003.65]
- 94 **Terashima T**, Kojima H, Fujimiya M, Matsumura K, Oi J, Hara M, Kashiwagi A, Kimura H, Yasuda H, Chan L. The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. *Proc Natl Acad Sci USA* 2005; **102**: 12525-12530 [PMID: 16116088 DOI: 10.1073/pnas.0505717102]
- 95 **Nickola TJ**, Ignatowski TA, Reynolds JL, Spengler RN. Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. *J Pharmacol Exp Ther* 2001; **297**: 680-687 [PMID: 11303058]
- 96 **Renauld AE**, Spengler RN. Tumor necrosis factor expressed by primary hippocampal neurons and SH-SY5Y cells is regulated by alpha(2)-adrenergic receptor activation. *J Neurosci Res* 2002; **67**: 264-274 [PMID: 11782970 DOI: 10.1002/jnr.10101]
- 97 **Qiu J**, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, Moskowitz MA. Early release of HMGB-1 from neurons after the onset of brain ischemia. *J Cereb Blood Flow Metab* 2008; **28**: 927-938 [PMID: 18000511 DOI: 10.1038/sj.jcbfm.9600582]
- 98 **Smallwood RF**, Laird AR, Ramage AE, Parkinson AL, Lewis J, Clauw DJ, Williams DA, Schmidt-Wilcke T, Farrell MJ, Eickhoff SB, Robin DA. Structural brain anomalies and chronic pain: a quantitative meta-analysis of gray matter volume. *J Pain* 2013; **14**: 663-675 [PMID: 23685185 DOI: 10.1016/j.jpain.2013.03.001]
- 99 **Araújo EP**, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB, Saad MJ, Velloso LA. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. *Endocrinology* 2007; **148**: 5991-5997 [PMID: 17761768 DOI: 10.1210/en.2007-0132]

**P- Reviewer:** Afzal M, Ajmal M, Chen C, Mentos O  
**S- Editor:** Cui LJ **L- Editor:** A **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

